Kubient (OTC:KBNT) Stock, Quote.Headers.trade-ideas

Kubient

Kubient Inc has developed a cloud-based software platform for real-time trading of digital, programmatic advertising. The platform allows both advertisers and publishers to use machine learning during any programmatic ad space auction.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ARCT

ASTS

ATOM

AYTU

BTDR

CHGG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CRMD

DADA

EGOX

ELIQ

EVLO

FTCH

GLBE

GYRE

HRTX

HRYU

HSCS

ICVX

IHRT

INTA

INTZ

ISPR

JGGC

KBNT

KNTE

MGOL

MNTS

MRAI

MYTE

PRSO

RBOT

SDOT

SGMO

SHPW

SLDB

SLNH

SPRC

SXTP

TIVC

TRIP

TRKA

TSHA

VLCN

Vintage Wine Estates, Inc. - Common Stock

XAIR

Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.

Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

AUVI

BCDA

INVO

SKIN

THRX

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 500 points on Tuesday.

The Dow traded up 1.60% to 34,885.58 while the NASDAQ rose 2.50% to 14,111.61. The S&amp;P 500 also rose, gaining, 2.06% to 4,502.40.

Dow Jumps Over 500 Points; Home Depot Earnings Top Views

ABSI

ACIC

ADPT

AIRE

AKLI

AMRC

ASUR

BENF

BTAI

CUTR

DHAC

EVOK

GMDA

HOUS

HROW

HYZN

JANX

LICY

LYEL

MSTR

NOVA

NPWR

PACB

PLUG

PODC

PRTG

PXMD

RDHL

RNLX

RWAY

SALM

SNAP

SPCB

TCON

TENX

TLIS

UNIT

Shares of Beyond Air, Inc.  (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results.

Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Kubient Inc

H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) has outperformed the market over the past 5 years by 2.77% on an annualized basis producing an average annual return of 15.37%. Currently, H&amp;R Block has a market capitalization of $7.95 billion. 
Buying $1000 In HRB: If an investor had bought $1000 of HRB stock 5 years ago, it would be worth $2,049.30 today based on a price of $56.95 for HRB at the time of writing.
<h3>H&amp;R Block's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029438_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 16.62%. Currently, Apollo Global Management has a market capitalization of $69.51 billion. 
Buying $1000 In APO: If an investor had bought $1000 of APO stock 10 years ago, it would be worth $4,546.33 today based on a price of $122.16 for APO at the time of writing.
<h3>Apollo Global Management's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722029433_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Apollo Global Management 10 Years Ago Would Be Worth This Much Today

Citigroup analyst Atif Malik maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Buy and lowers the price target from $185 to $162.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Teradyne, Lowers Price Target to $162

During the last three months, 5 analysts shared their evaluations of Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027698_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Puma Biotechnology is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Puma Biotechnology. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Puma Biotechnology compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Puma Biotechnology's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Puma Biotechnology's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PBYI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Puma Biotechnology analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Puma Biotechnology</h2>
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
<h3>A Deep Dive into Puma Biotechnology's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Puma Biotechnology's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -17.07%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Puma Biotechnology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -11.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Puma Biotechnology's ROE stands out, surpassing industry averages. With an impressive ROE of -9.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Puma Biotechnology's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.17, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PBYI

Where Puma Biotechnology Stands With Analysts

During the last three months, 10 analysts shared their evaluations of Lennox Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LII#NYSE">LII</a>), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Lennox Intl, presenting an average target of $581.9, a high estimate of $675.00, and a low estimate of $517.00. This upward trend is apparent, with the current average reflecting a 7.66% increase from the previous average price target of $540.50.
<img src="https://www.benzinga.com/files/images/story/2024/1722027675_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Lennox Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$550.00</td>
<td>$517.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$675.00</td>
<td>$675.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$572.00</td>
<td>$566.00</td>
</tr>
<tr>
<td>Jeffrey Hammond</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$610.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$517.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Joe Ritchie</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$507.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$570.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Gautam Khanna</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Joseph O'Dea</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$550.00</td>
<td>$520.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Lennox Intl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Lennox Intl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Lennox Intl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Lennox Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LII/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lennox Intl analyst ratings.</a>
<h2>Delving into Lennox Intl's Background</h2>
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2023, residential HVAC was 68% of sales and commercial HVAC and Heatcraft refrigeration was 32% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.
<h3>Unraveling the Financial Story of Lennox Intl</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Lennox Intl showcased positive performance, achieving a revenue growth rate of 2.81% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.95%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Lennox Intl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 51.98% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Lennox Intl's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Lennox Intl's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.72, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Lennox Intl

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 10 years by 12.34% on an annualized basis producing an average annual return of 23.26%. Currently, Taiwan Semiconductor has a market capitalization of $837.03 billion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 10 years ago, it would be worth $7,815.64 today based on a price of $161.40 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027659_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 10 Years Ago Would Be Worth This Much Today

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 5 years by 9.75% on an annualized basis producing an average annual return of 22.36%. Currently, Canadian Natural Res has a market capitalization of $73.53 billion. 
Buying $100 In CNQ: If an investor had bought $100 of CNQ stock 5 years ago, it would be worth $279.38 today based on a price of $34.42 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722027654_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Canadian Natural Res Stock In The Last 5 Years

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.5, with a high estimate of $22.50 and a low estimate of $22.50. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1722027642_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.50</td>
<td>$22.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Betterware de Mexico SAPI's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Betterware de Mexico SAPI's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Betterware de Mexico SAPI analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.
<h3>A Deep Dive into Betterware de Mexico SAPI's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Betterware de Mexico SAPI's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 10.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Betterware de Mexico SAPI's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 19.7%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.68%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 3.6, Betterware de Mexico SAPI adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BWMX

Critical Insights From Betterware de Mexico SAPI Analyst Ratings: What You Need To Know

Canaccord Genuity analyst Dalton Baretto maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$22 to C$23.

TSX:MAG

Canaccord Genuity Maintains Buy on MAG Silver, Raises Price Target to C$23

Canaccord Genuity analyst Mike Mueller maintains Baytex Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BTE#TSX">BTE</a>) with a Buy and raises the price target from C$6.25 to C$6.5.

TSX:BTE

Canaccord Genuity Maintains Buy on Baytex Energy, Raises Price Target to C$6.5

First Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCAP#NASDAQ">FCAP</a>) reported quarterly earnings of $0.85 per share. This is a 3.66 percent increase over earnings of $0.82 per share from the same period last year.

FCAP

First Cap Q2 EPS $0.85 Up From $0.82 YoY

Asset Sales

Johnson Controls International: Purchase Deal Says Robert Bosch Will Pay Co Termination Fee Of $300M If Purchase Agreement Is Terminated

PayPal Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NYSE">PYPL</a>) short percent of float has fallen 4.83% since its last report. The company recently reported that it has 20.55 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>PayPal Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for PayPal Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing PayPal Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, PayPal Holdings's peer group average for short interest as a percentage of float is 5.82%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

PYPL

How Is The Market Feeling About PayPal Holdings?

Owens-Corning's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) short percent of float has risen 10.34% since its last report. The company recently reported that it has 1.49 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Owens-Corning Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Owens-Corning has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Owens-Corning's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Owens-Corning's peer group average for short interest as a percentage of float is 4.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Owens-Corning's Recent Short Interest

Kohl's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 4.82% since its last report. The company recently reported that it has 40.73 million shares sold short, which is 51.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722026711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 9.12%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(KSS) - Analyzing Kohl's's Short Interest

<a href="https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393">https://www.ft.com/content/d67a6325-d316-4bb8-80e3-1d51429b3393</a>
Howard Schultz, the former Starbucks chief executive, is opposing a potential settlement between the company and activist investor Elliott Investment Management, in the latest sign of tension at the world's largest coffee chain. The quasi-founder of Starbucks has made his opposition to an Elliott settlement known to some board members, said people familiar with the matter. Schultz had criticised its leadership publicly in recent months despite no longer having a formal role at the company. He remains Starbucks's sixth-largest shareholder, with a holding of about $1.6bn. Elliott, known for being an aggressive investor, has built a sizeable minority stake in the $86bn company and has privately pushed for change in recent weeks, including board representation, in an attempt to revive Starbucks' lacklustre performance. Schultz and Elliott have not been in contact over this matter, one person said. Companies under pressure from activists such as Elliott often seek to negotiate agreements with them rather than face a public fight, but the status of any settlement discussions between Starbucks and Elliott remain unclear. "Howard left the board a year ago and in his limited contact with the board since, his input has always focused on the values and culture of Starbucks as the primary driver of success and performance," a person close to Schultz said. The billionaire former coffee machine salesman led the company three separate times — for about 14 years starting in 1986, then again from 2008 to 2017, and most recently as interim CEO from 2022 to 2023.&nbsp; He was succeeded as CEO last year by Laxman Narasimhan, who joined from UK-based consumer health and hygiene group Reckitt. Schultz remains chair emeritus but left the company's board and has said he does not have access to financial information.
 Schultz, who has said he has no interest in returning as CEO, has remained vocal on the sidelines. This spring he criticised the company's performance on LinkedIn, penning an open letter that said senior leaders and board members needed "to spend more time with those who wear the green apron". He also made an appearance on business podcast Acquired in June, speaking about the history of Starbucks and his recommendations for management. "It hasn't been a great year for Starbucks," he said. "In fairness to Laxman, there's a lot of external issues that have contributed to the pressure, like on every company. But the company has not executed the way that I think it should have." "If the company is doing a drift towards mediocrity, I hold leadership, and the board responsible for that," he said later in the three-hour podcast. Starbucks's share price has fallen about 20 per cent since the start of 2024. The company cut its financial guidance in January and again in April, when it reported a 4 per cent decline in quarterly comparable store sales that was the first such drop since late 2020. It is due to announce results for its fiscal third quarter on Tuesday. Starbucks has made changes to its board over the past year. Three new members, including the CEOs of YouTube and T-Mobile, Neal Mohan and Mike Sievert, joined earlier this year. This spring, Microsoft CEO Satya Nadella left the board. Spokespeople for Schultz, Starbucks and Elliott declined to comment.

Legal

Management

SBUX

'Howard Schultz Opposes Starbucks Settlement With Activist Investor Elliott' - Financial Times

Offerings

ALRN

Aileron Therapeutics Got Into Equity Distribution Agreement, May Offer & Sell Shares Of Our Common Stock From Time To Time Of Up To $50M

WIIM

VTVT

vTv Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 phase 3 trial in type 1 diabetes.

vTv Therapeutics Shares Resume Trade

Paragon Technologies, Inc. ("Paragon"), a diversified holding company and a large shareholder of Ocean Power Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NYSE">OPTT</a>), ("Company" or "OPT"), issues the following statement to OPT shareholders:
On July 5, OPT filed a proxy statement calling for a special meeting of shareholders on August 30, 2024, asking shareholders to approve increasing the Company's authorized shares to 200 million, up from 100 million.
On July 25, 2025, OPT announced Fiscal 2024 financial results revealing that it lost $27.4 million in fiscal 2024 versus $26.3 million in fiscal 2023.

OPTT

PGNT

Paragon Technologies Recommends Ocean Power Shareholders Vote AGAINST Its Plan To Increase Its Authorized Shares By 100M

Warning: KBNT is at high risk of performing badly

Kubient receives Nasdaq notice of non-compliance

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the week with a breakdown of the biggest pre-market stock movers for Monday!
Moving stocks this morning are news drone announcements, layoffs, a delisting notice and more.
Let&rsquo;s get into that news below!

<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>ParaZero Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/przo-stock-quote/">PRZO</a>) stock is rocketing more than 56% as it continues to rally <a href="https://investorplace.com/2023/10/why-is-parazero-technologies-przo-stock-up-58-today/">on drone flight approval</a>.</li>
<li>Maris Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mtek-stock-quote/">MTEK</a>) shares are soaring 29% after <a href="https://www.nasdaq.com/market-activity/stocks/mtek/press-releases">launching its Jupiter Drones product</a>.</li>
<li>Gaucho Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/vino-stock-quote/">VINO</a>) stock is surging over 27% without any clear news on Monday morning.</li>
<li>Creative Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) shares are gaining more than 18% despite a lack of news today.</li>
<li>Kwesst Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is increasing over 18% on Monday.</li>
<li>Vaccitech (NASDAQ:<a href="https://investorplace.com/stock-quotes/vacc-stock-quote/">VACC</a>) shares are rising more than 14% this morning.</li>
<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is heading close to 14% higher as it bounces back from a fall on Friday.</li>
<li>Akso Health Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/ahg-stock-quote/">AHG</a>) shares are climbing over 10% on Monday morning.</li>
<li>Molekule (NASDAQ:<a href="https://investorplace.com/stock-quotes/mkul-stock-quote/">MKUL</a>) stock is jumping more than 9% today.</li>
<li>Xortx Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/xrtx-stock-quote/">XRTX</a>) shares are up over 9% today.</li>
</ol>
<h2>10 Top Losers</h2>
<ol>
<li>Shift Technologies&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sft-stock-quote/">SFT</a>) stock is crashing nearly 85% alongside <a href="https://www.nasdaq.com/press-release/shift-technologies-inc.-to-file-voluntary-chapter-11-petition-2023-10-06">bankruptcy filing news</a>.</li>
<li>LQR House (NASDAQ:<a href="https://investorplace.com/stock-quotes/lqr-stock-quote/">LQR</a>) shares are plummeting almost 29% following a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317794285&amp;type=PDF&amp;symbol=LQR&amp;cdn=706fa52b2ec8e8c687354fb1712ec138&amp;companyName=LQR+House+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2023-10-06">proposed public offering</a>.</li>
<li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is diving more than 19% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317793738&amp;type=PDF&amp;symbol=KBNT&amp;cdn=647a5bf47c9ef61cf57c70edb0299b87&amp;companyName=Kubient+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-10-06">after announcing layoffs</a>.</li>
<li>Falcons Beyond Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/fbyd-stock-quote/">FBYD</a>) shares are taking an over 17% beating this morning.</li>
<li>Grom Social Enterprises (NASDAQ:<a href="https://investorplace.com/stock-quotes/grom-stock-quote/">GROM</a>) stock is sliding more than 12% on Monday morning.</li>
<li>Ondas (NASDAQ:<a href="https://investorplace.com/stock-quotes/onds-stock-quote/">ONDS</a>) shares are tumbling over 12% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317794245&amp;type=PDF&amp;symbol=ONDS&amp;cdn=f454b5395f9b928ae7dae3fc17658b04&amp;companyName=Ondas+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-10-06">getting a delisting notice</a>.</li>
<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) stock is decreasing more than 12% <a href="https://www.nasdaq.com/press-release/novo-integrated-sciences-provides-update-on-certain-current-events-2023-10-06">following a company update</a>.</li>
<li>Enlight Renewable Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/enlt-stock-quote/">ENLT</a>) shares are dropping close to 11% today.</li>
<li>Alarum Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/alar-stock-quote/">ALAR</a>) stock is decreasing over 10% this morning.</li>
<li>BrainsWay (NASDAQ:<a href="https://investorplace.com/stock-quotes/bway-stock-quote/">BWAY</a>) shares close out our pre-market stock movers down more than 10%.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766529">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/10/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-oct-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about!



Moving stocks this morning are delisting notices, earnings reports and more.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>ReAlpha Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/aire-stock-quote/">AIRE</a>) stock is rocketing more than 70% alongside heavy pre-market trading.</li>



<li>Alaunos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcrt-stock-quote/">TCRT</a>) shares are surging 45% with strong early morning trading.</li>



<li>Theseus Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/thrx-stock-quote/">THRX</a>) stock is soaring over 35% after announcing plans to <a href="https://www.nasdaq.com/press-release/theseus-pharmaceuticals-announces-process-to-explore-strategic-alternatives-2023-11">explore strategic alternatives</a>.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) shares are rising more than 33% with the release of its <a href="https://www.prnewswire.com/news-releases/invo-reports-record-third-quarter-2023-financial-results-301986483.html">Q3 2023 earnings report</a>.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) stock is gaining close to 33% without any clear news this morning.</li>



<li>Redhill Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdhl-stock-quote/">RDHL</a>) shares are increasing over 19% despite a lack of news today.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) stock is heading more than 16% higher on Tuesday morning.</li>



<li>Absci (NASDAQ:<a href="https://investorplace.com/stock-quotes/absi-stock-quote/">ABSI</a>) shares are jumping 16% after announcing a <a href="https://www.nasdaq.com/press-release/almirall-and-absci-announce-ai-drug-discovery-partnership-to-rapidly-develop-novel-0">drug discovery partnership</a>.</li>



<li>BioNexus Gene Lab (NASDAQ:<a href="https://investorplace.com/stock-quotes/bglc-stock-quote/">BGLC</a>) stock is getting an over 15% boost <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317859801&amp;type=PDF&amp;symbol=BGLC&amp;cdn=70565f2969e4e9dd9b19f3c5cd70639b&amp;companyName=BioNexus+Gene+Lab+Corp&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-13">despite a delisting notice</a>.</li>



<li>PaxMedica (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/">PXMD</a>) shares are up more than 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Beauty Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/skin-stock-quote/">SKIN</a>) stock is crashing over 52% after <a href="https://finance.yahoo.com/news/beautyhealth-reports-third-quarter-2023-211000160.html">failing to impress in Q3</a>.</li>



<li>Trivago (NASDAQ:<a href="https://investorplace.com/stock-quotes/trvg-stock-quote/">TRVG</a>) shares are plummeting 44% following <a href="https://www.nasdaq.com/press-release/trivago-announces-ex-dividend-date-for-extraordinary-dividend-and-updates-effective">a ratio change</a>.</li>



<li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is diving more than 40% as it <a href="https://www.nasdaq.com/press-release/kubient-announces-voluntary-delisting-from-the-nasdaq-capital-market-2023-11-13">plans to delist its shares</a>.</li>



<li>Applied UV (NASDAQ:<a href="https://investorplace.com/stock-quotes/auvi-stock-quote/">AUVI</a>) shares are taking an over 28% beating with the <a href="https://www.nasdaq.com/press-release/applied-uv-announces-selected-preliminary-third-quarter-2023-financial-results-2023">release of preliminary earnings</a>.</li>



<li>Harrow (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrow-stock-quote/">HROW</a>) stock is tumbling almost 25% alongside its <a href="https://www.nasdaq.com/press-release/harrow-announces-third-quarter-2023-financial-results-2023-11-13">Q3 earnings report</a>.</li>



<li>Akili (NASDAQ:<a href="https://investorplace.com/stock-quotes/akli-stock-quote/">AKLI</a>) shares are sliding more than 19% on Tuesday morning.</li>



<li>Canadian Solar (NASDAQ:<a href="https://investorplace.com/stock-quotes/csiq-stock-quote/">CSIQ</a>) stock is decreasing over 15% on <a href="https://www.marketwatch.com/story/canadian-solar-profit-revenue-fall-in-3q-on-softer-demand-97712881">weak Q3 earnings</a>.</li>



<li>Peraso (NASDAQ:<a href="https://investorplace.com/stock-quotes/prso-stock-quote/">PRSO</a>) shares are slipping more than 14% with the release of <a href="https://www.sfchronicle.com/business/article/peraso-q3-earnings-snapshot-18489214.php">Q3 earnings results</a>.</li>



<li>GlucoTrack (NASDAQ:<a href="https://investorplace.com/stock-quotes/gctk-stock-quote/">GCTK</a>) stock is dipping nearly 14% today.</li>



<li>Fisker (NYSE:<a href="https://investorplace.com/stock-quotes/fsr-stock-quote/">FSR</a>) shares close out our pre-market stock movers down over 13% on <a href="https://www.cnbc.com/2023/11/13/fisker-fsr-earnings-report-q3-2023.html">lackluster Q3 results</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-nov-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Wednesday!



Earnings reports are the hot topic on Wednesday as investors react to results for the third quarter of 2023.



Let&rsquo;s get into that news down below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock is rocketing more than 79% alongside heavy pre-market trading.</li>



<li>MGO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) shares are soaring over 44% with the release of its <a href="https://finance.yahoo.com/news/mgo-global-announces-third-quarter-211500882.html">Q3 earnings report</a>.</li>



<li>Solid Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/sldb-stock-quote/">SLDB</a>) stock is surging close to 33% after <a href="https://www.nasdaq.com/market-activity/stocks/sldb/press-releases">getting an investigational new drug (IND) application</a> for its Muscular Dystrophy gene therapy candidate.</li>



<li>Ucommune International (NASDAQ:<a href="https://investorplace.com/stock-quotes/uk-stock-quote/">UK</a>) shares are gaining more than 20% without any clear news this morning.</li>



<li>GDEV (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdev-stock-quote/">GDEV</a>) stock is rising over 19% despite a lack of news today.</li>



<li>Arcturus Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/arct-stock-quote/">ARCT</a>) shares are increasing more than 19% alongside its <a href="https://www.nasdaq.com/press-release/arcturus-therapeutics-announces-third-quarter-2023-financial-update-and-pipeline">latest earnings release</a>.</li>



<li>Edgio (NASDAQ:<a href="https://investorplace.com/stock-quotes/egio-stock-quote/">EGIO</a>) stock is heading over 18% higher with a <a href="https://seekingalpha.com/news/4036765-edgio-reports-mixed-q3-earnings-initiates-q4-and-updates-fy23-outlook">mixed Q3 earnings report</a>.</li>



<li>Cormedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/crmd-stock-quote/">CRMD</a>) shares are jumping nearly 18% after <a href="https://finance.yahoo.com/news/cormedix-inc-crmd-reports-increased-230348395.html">releasing its earnings report for Q3</a>.</li>



<li>Heron Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrtx-stock-quote/">HRTX</a>) stock is climbing more than 16% with its <a href="https://www.sfchronicle.com/business/article/heron-therapeutics-q3-earnings-snapshot-18491644.php">latest earnings data</a>.</li>



<li>Kintara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ktra-stock-quote/">KTRA</a>) shares are up over 15% with strong early morning trading. </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is diving more than 20% as it <a href="https://finance.yahoo.com/news/kubient-announces-voluntary-delisting-nasdaq-230100862.html">prepares to be delisted</a>.</li>



<li>Mobiquity Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/mobq-stock-quote/">MOBQ</a>) shares are tumbling over 14% alongside its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317866535&amp;type=PDF&amp;symbol=MOBQ&amp;cdn=953a74af2a42e8759ffaab30973a82af&amp;companyName=Mobiquity+Technologies+Inc.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2023-11-14">latest earnings data</a>.</li>



<li>Marpai (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrai-stock-quote/">MRAI</a>) stock is taking a more than 14% beating on Wednesday morning.</li>



<li>Intrusion (NASDAQ:<a href="https://investorplace.com/stock-quotes/intz-stock-quote/">INTZ</a>) shares are sliding over 13% after <a href="https://www.nasdaq.com/press-release/intrusion-inc.-reports-third-quarter-2023-results-2023-11-14">releasing Q3 results</a>.</li>



<li>Ispire Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispr-stock-quote/">ISPR</a>) stock is dropping more than 13% today.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are decreasing by almost 13% as they come off a recent rally.</li>



<li>Kidpik (NASDAQ:<a href="https://investorplace.com/stock-quotes/pik-stock-quote/">PIK</a>) stock is falling over 12% after <a href="https://www.investing.com/news/kidpik-earnings-missed-by-004-revenue-fell-short-of-estimates-3234275">missing Q3 estimates</a>.</li>



<li>Silo Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) shares are slipping more than 11% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317867354&amp;type=PDF&amp;symbol=SILO&amp;cdn=05a895e1af575c9b99c0efff7637a5d6&amp;companyName=Silo+Pharma+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-14">updating drug development milestones</a>.</li>



<li>Advance Auto Parts (NYSE:<a href="https://investorplace.com/stock-quotes/aap-stock-quote/">AAP</a>) stock is dipping close to 11% on <a href="https://www.morningstar.com/news/marketwatch/20231115213/advance-auto-parts-stock-sinks-after-a-surprise-large-loss-while-sales-topped-expectations">a surprise negative EPS</a>.</li>



<li>Motus GI (NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/">MOTS</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-nov-15th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kubient&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is falling hard on Wednesday as investors prepare for the company&rsquo;s shares<a href="https://finance.yahoo.com/news/kubient-announces-voluntary-delisting-nasdaq-230100862.html"> to be delisted</a> in the near future.



Kubient&nbsp;is voluntarily delisting its shares after struggling to regain compliance with Nasdaq listing standards. As a result, the company&rsquo;s stock will be suspended from trading on the exchange starting on Nov. 17.



Following that suspension, Kubient&nbsp;will file a Form 25 with the Securities and Exchange Commission (SEC) for the delisting of its shares and warrants. The company says that its shares will be delisted no sooner than 10 days after this filing.



Kubient&nbsp;faced several problems with its listing that resulted in this decision. That includes its share price remaining below $1 for too long, as well as filing a timely filing of its Form 10-Q quarterly report. Kubient&rsquo;s Board decided delisting was the best path forward for the company to avoid costs and other burdens connected to remaining public.



<h2>KBNT Stock Movement Today</h2>



Shares of KBNT stock are seeing heavy trading today as its delisting approaches. As of this writing, more than 215,000 shares have changed hands. For the record, the company&rsquo;s daily average trading volume is about 163,000 shares.



KBNT stock is down 14.1% as of Wednesday morning.



Investors seeking out even more of the most recent stock market stories will want to stick around!



We&rsquo;re offering up insight into all of the hottest stock market news traders need to know about on Wednesday! A few examples include what&rsquo;s rising MGO Global&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) and Heart Test Laboratories&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock today, as well as the biggest pre-market stock movers this morning. All of that news is ready to go at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/11/why-is-mgo-global-mgol-stock-up-31-today/">Why Is MGO Global (MGOL) Stock Up 31% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-heart-test-laboratories-hscs-stock-up-43-today/">Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-nov-15th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">Why Is Kubient (KBNT) Stock Down 14% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Kubient (KBNT) Stock Down 14% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Mobiquity Technologies&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mobq-stock-quote/">MOBQ</a>) stock is on the move Wednesday after the company released its most recent earnings data.



The latest earnings data from the company includes diluted earnings per share of -38 cents. That&rsquo;s a massive improvement over the -$3.90 that was reported in the same period of the year prior. A lack of analysts coverage means there&rsquo;s no estimate to compare this information to.



Moving on to revenue, Mobiquity Technologies brought in $177,271. That&rsquo;s worse than the $904,223 reported during the third quarter of 2022. Yet again, there are no analyst estimates to compare this to.



Mobiquity Technologies also includes the following warning in its earnings report.




&ldquo;Without sufficient revenues from operations, if the Company does not obtain additional capital, the Company will be required to reduce the scope of its business development activities or cease operations. The Company may explore obtaining additional capital financing and the Company is closely monitoring its cash balances, cash needs, and expense levels.&rdquo;




<h2>MOBQ Stock Movement on Wednesday</h2>



Mobiquity Technologies stock is seeing strong trading volume this morning with some 29,000 shares changing hands. That&rsquo;s closing in on its daily average trading volume of about 32,000 shares.



Investors will also note that shares of MOBQ stock are down 2.6% as of Wednesday morning.



There&rsquo;s plenty more stock market news that traders will want to know about below!



We&rsquo;ve got all of the hottest stock market news that investors need to know about on Wednesday! That includes what&rsquo;s going on with shares of Kubient&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock, MGO Global&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mgol-stock-quote/">MGOL</a>) stock and Heart Test Laboratories&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">Why Is Kubient (KBNT) Stock Down 14% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-mgo-global-mgol-stock-up-31-today/">Why Is MGO Global (MGOL) Stock Up 31% Today?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-heart-test-laboratories-hscs-stock-up-43-today/">Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/why-is-mobiquity-technologies-mobq-stock-down-today/">Why Is Mobiquity Technologies (MOBQ) Stock Down Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Mobiquity Technologies (MOBQ) Stock Down Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sirius XM (NASDAQ:<a href="https://investorplace.com/stock-quotes/siri-stock-quote/">SIRI</a>) stock is on the rise Wednesday after Warren Buffett revealed his <a href="https://www.cnbc.com/2023/11/15/stocks-making-the-biggest-premarket-moves-.html">purchase of the company&rsquo;s shares</a> during Q3.



A filing with the Securities and Exchange Commission (SEC) highlights that the billionaire investor <a href="https://www.gurufocus.com/guru/warren%2Bbuffett/stock-picks?view=table">acquired 9,683,224 shares</a> of SIRI stock during the third quarter of the year. Investors will also note that this is a new investment for Buffett as he previously didn&rsquo;t hold any shares of SIRI stock.



Warren Buffett taking a stake in SIRI stock is big news for the company. Many traders follow Buffett&rsquo;s investment strategies when making their own stock purchases. That means some will see his purchase of SIRI shares as a sign of confidence in the company and may choose to follow suit with their own investments.



<h2>SIRI Stock Reactions on Wednesday</h2>



SIRI stock is seeing a decent amount of activity on Wednesday as investors react to the Warren Buffett investment news. That has more than 5 million shares of the stock changing hands today. To put that in perspective, the company&rsquo;s daily average trading volume is still a good bit above that at roughly 14.9 million shares.



SIRI stock is up 7.5% as of Wednesday morning following the Buffett news. However, traders will note that SIRI shares are still down 9.1% since the start of the year.



Investors that are looking for even more of the most recent stock market stories will want to keep reading!



We&rsquo;re offering all of the latest stock coverage that traders need to know about on Wednesday! Among that is another update on Buffet&rsquo;s investments, as well as what&rsquo;s happening with shares of Mobiquity Technologies&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mobq-stock-quote/">MOBQ</a>) and Kubient&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock today. You can find out more on these matters at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2023/11/is-warren-buffett-giving-up-on-general-motors-gm-stock/">Is Warren Buffett Giving Up on General Motors (GM) Stock?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-mobiquity-technologies-mobq-stock-down-today/">Why Is Mobiquity Technologies (MOBQ) Stock Down Today?</a></li>



<li><a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">Why Is Kubient (KBNT) Stock Down 14% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/why-is-sirius-xm-siri-stock-up-8-today/">Why Is Sirius XM (SIRI) Stock Up 8% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sirius XM (SIRI) Stock Up 8% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday!



Moving stocks are earnings reports, public offerings, insider buying and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is rocketing more than 44% alongside heavy pre-market trading.</li>



<li>BioVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/bivi-stock-quote/">BIVI</a>) shares are soaring over 19% without any clear news this morning.</li>



<li>Heart Test Laboratories (NASDAQ:<a href="https://investorplace.com/stock-quotes/hscs-stock-quote/">HSCS</a>) stock is surging more than 17% with strong early morning trading.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) shares are gaining close to 16% despite any apparent news this morning.</li>



<li>Flora Growth (NASDAQ:<a href="https://investorplace.com/stock-quotes/flgc-stock-quote/">FLGC</a>) stock is rising over 15% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871899&amp;type=PDF&amp;symbol=FLGC&amp;cdn=5882e28b5f1d979fb6e3d46dd126c4e3&amp;companyName=Flora+Growth+Corp.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2023-11-15">alongside insider buying</a>.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are increasing more than 13% with its <a href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-snti/senti-biosciences/news/senti-biosciences-third-quarter-2023-earnings-eps-beats-expe">latest earnings release</a>.</li>



<li>Esports Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmbl-stock-quote/">GMBL</a>) stock is climbing over 13% with heavy early morning trading.</li>



<li>Acutus Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/afib-stock-quote/">AFIB</a>) shares are jumping more than 13% with strong trading today.</li>



<li>Isun (NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/">ISUN</a>) stock is heading 13% higher with its <a href="https://www.nasdaq.com/press-release/isun-inc.-reports-third-quarter-2023-results-2023-11-14">most recent earnings release</a>.</li>



<li>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) shares are up over 12% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is crashing more than 46% as a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317850450&amp;type=PDF&amp;symbol=VLCN&amp;cdn=001b639a9f2126eaa0bf523d5e221ead&amp;companyName=Volcon+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2023-11-08">public offering goes into effect</a>. </li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving over 27% after <a href="https://www.nasdaq.com/press-release/augmedix-announces-pricing-of-upsized-public-offering-of-6250000-shares-of-common">pricing a public offering</a>.</li>



<li>Kubient (NASDAQ:<a href="https://investorplace.com/stock-quotes/kbnt-stock-quote/">KBNT</a>) stock is plummeting more than 17% <a href="https://investorplace.com/2023/11/why-is-kubient-kbnt-stock-down-14-today/">as its delisting approaches</a>.</li>



<li>Velo3D (NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/">VLD</a>) shares are taking an over 15% beating after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317871328&amp;type=PDF&amp;symbol=VLD&amp;cdn=8f1f75ec001d1505c7491375cf77935b&amp;companyName=Velo3D+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-11-15">adjusting its Q3 earnings report</a>.</li>



<li>Alpine 4 (NASDAQ:<a href="https://investorplace.com/stock-quotes/alpp-stock-quote/">ALPP</a>) stock is tumbling more than 14% on Thursday morning.</li>



<li>Gaucho Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/vino-stock-quote/">VINO</a>) shares are sliding over 13% this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is decreasing more than 13% today.</li>



<li>Siyata Mobile (NASDAQ:<a href="https://investorplace.com/stock-quotes/syta-stock-quote/">SYTA</a>) shares are falling over 12% after <a href="https://za.investing.com/news/siyata-mobile-earnings-missed-by-100-revenue-fell-short-of-estimates-2934605">missing estimates in Q3</a>. </li>



<li>Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) stock is slipping more than 12% as it comes off a recent rally.</li>



<li>Sadot (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdot-stock-quote/">SDOT</a>) shares closed out our pre-market stock movers down over 12% after <a href="https://finance.yahoo.com/news/sadot-group-inc-reports-third-213000334.html">missing EPS estimates in Q3</a>.</li>
</ol>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771243">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
		<div>
			<div></div>
						<div></div>
					</div>
	</div>The post <a href="https://investorplace.com/2023/11/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-nov-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Kubient (KBNT) has issued an announcement. Kubient, Inc. is slashing its workforce by 50%, which equates to two employees, as part of a strategy to...

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Kubient

Kubient (KBNT) Forecast

Kubient (OTC:KBNT) Stock, Quote.Headers.trade-ideas